Borderline resectable pancreatic cancer (BRPC), Pancreatic cancer, Resectable pancreatic cancer (RPC)
Conditions
Brief summary
Progression free survival, defined as the time from inclusion to the clinical trial to disease recurrence/progression or death from any cause
Detailed description
Overall survival, Resection rate, pR0 resection rate, Postoperative complications, Toxicity, Quality of life (QoL), Completion of neoadjuvant chemotherapy, Completion of neoadjuvant immunotherapy, Radiological response rate, Serum CA 19-9 response, Serum CEA response, Pathologic response, Immune responses, sR0 resection rate, Completion of adjuvant chemotherapy, Completion of neoadjuvant SABR, Completion of adjuvant immunotherapy, lymph node tumor-negative resection rate
Interventions
DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion
Sponsors
Amsterdam UMC
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression free survival, defined as the time from inclusion to the clinical trial to disease recurrence/progression or death from any cause | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, Resection rate, pR0 resection rate, Postoperative complications, Toxicity, Quality of life (QoL), Completion of neoadjuvant chemotherapy, Completion of neoadjuvant immunotherapy, Radiological response rate, Serum CA 19-9 response, Serum CEA response, Pathologic response, Immune responses, sR0 resection rate, Completion of adjuvant chemotherapy, Completion of neoadjuvant SABR, Completion of adjuvant immunotherapy, lymph node tumor-negative resection rate | — |
Countries
Netherlands
Outcome results
None listed